Edition:
India

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

105.55USD
17 Aug 2018
Change (% chg)

$1.19 (+1.14%)
Prev Close
$104.36
Open
$104.43
Day's High
$105.92
Day's Low
$104.30
Volume
965,619
Avg. Vol
983,582
52-wk High
$105.92
52-wk Low
$73.70

Chart for

About

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.... (more)

Overall

Beta: 0.35
Market Cap(Mil.): $95,874.12
Shares Outstanding(Mil.): 1,100.99
Dividend: 0.52
Yield (%): 2.39

Financials

  LLY.N Industry Sector
P/E (TTM): 37.74 30.93 32.76
EPS (TTM): 2.31 -- --
ROI: 8.49 15.07 14.61
ROE: 17.03 16.59 16.33

Deals of the day-Mergers and acquisitions

July 24 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Tuesday:

25 Jul 2018

Lilly plans Elanco IPO, posts quarterly profit above estimates

Eli Lilly and Co said on Tuesday it would take its Elanco animal health business public and posted a better-than-expected quarterly profit, helped by demand for its diabetes drugs Trulicity and Humalog.

24 Jul 2018

Eli Lilly posts quarterly loss

July 24 Eli Lilly and Co posted a second-quarter loss on Tuesday, hurt by acquisition-related charges to the tune of $1.62 billion.

24 Jul 2018

Pfizer-Lilly pain drug meets late-stage trial goals

An experimental osteoarthritis drug developed by Pfizer Inc and Eli Lilly and Co achieved its main goal of lowering pain in a late stage trial, the companies said on Wednesday, potentially offering a safer alternative to opioids.

18 Jul 2018

Pfizer-Lilly pain drug found effective in late-stage study

July 18 An experimental drug developed by Pfizer Inc and Eli Lilly and Co achieved its main goal of reducing pain in osteoarthritis patients in a late stage trial, the companies said on Wednesday.

18 Jul 2018

Novo reveals more Ozempic data on change in body weight by baseline BMI

COPENHAGEN, June 23 Diabetes drugmaker Novo Nordisk presented a post-hoc analysis of the SUSTAIN 7 trial comparing treatment effect in body weight across baseline BMI subgroups receiving Novo's Ozempic or Eli Lilly's dulaglutide, marketed as Trulicity.

23 Jun 2018

UPDATE 2-Lilly gets U.S. nod for arthritis drug, sets price well below rivals

* Drug priced at $25,000/year, 60 pct lower to AbbVie's Humira

01 Jun 2018

Novo Nordisk's oral diabetes drug beats Jardiance in study

LONDON, May 29 An experimental diabetes pill from Novo Nordisk proved better at lowering blood sugar levels than Eli Lilly and Boehringer Ingelheim's established Jardiance in a clinical study, the Danish drugmaker said on Tuesday.

29 May 2018

REFILE-UPDATE 5-Zoetis to buy veterinary diagnostics firm Abaxis for $1.9 bln

* Zoetis says diagnostics should grow faster than animal health

16 May 2018

Lilly to buy cancer drug developer AurKa Pharma

Eli Lilly and Co will buy AurKa Pharma Inc in a deal potentially worth up to $575 million, the U.S. drugmaker said on Monday, seeking access to the privately-held firm's experimental cancer treatment for solid tumors.

14 May 2018

Competitors

Earnings vs. Estimates